Announcements Trials
Browse Landscape

Phase

Phase 2 46Phase 1 18Phase 3 16Phase 1/2 12Phase 2/3 2Phase EARLY_PHASE1 1Phase 4 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration-resistant Prostate Cancer 1

Interventions

Letrozole 6Tamoxifen 4Cisplatin 4Anastrozole 4ribociclib 3exemestane 3Vancomycin 3Specimen Handling 3Nivolumab 3Magnetic Resonance Spectroscopy 3Human Papillomavirus Recombinant Vaccine nonavalent 3Dexamethasone 3Carboplatin 3Bevacizumab 3trametinib 2toripalimab 2encorafenib 2dabrafenib 2binimetinib 2atezolizumab 2asciminib 2Vincristine 2Sodium Chloride 2Rituximab 2Prednisone 2Papillomavirus Vaccines 2Methotrexate 2Medroxyprogesterone Acetate 2Lenalidomide 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × olaparib × 90 days × Clear all
NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

AstraZeneca

Phase 4 Active not recruiting
43 enrolled 16 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡